ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) Common Stock: €52.32 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:R9Z ImmuneOnco Biopharmaceuticals (Shanghai) Inc FRA:R9Z
6 GF Score
Price €0.37
! 5 Warning Signs
View Full Analysis

What is ImmuneOnco Biopharmaceuticals (Shanghai) Common Stock?

ImmuneOnco Biopharmaceuticals (Shanghai) FRA:R9Z +11.52% 6 Common Stock is €52.32 Mil as of Dec. 2025. GuruFocus rates FRA:R9Z with a GF Score™ of 6/100. The stock has 5 warning signs investors should review.

ImmuneOnco Biopharmaceuticals (Shanghai)'s quarterly common stock declined from Dec. 2024 (€53.43 Mil) to Jun. 2025 (€49.18 Mil) but then increased from Jun. 2025 (€49.18 Mil) to Dec. 2025 (€52.32 Mil).

ImmuneOnco Biopharmaceuticals (Shanghai)'s annual common stock increased from Dec. 2023 (€48.05 Mil) to Dec. 2024 (€53.43 Mil) but then declined from Dec. 2024 (€53.43 Mil) to Dec. 2025 (€52.32 Mil).

ImmuneOnco Biopharmaceuticals (Shanghai) Common Stock Historical Data

* Premium members only.

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuneOnco Biopharmaceuticals (Shanghai) Common Stock Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
0.96 48.22 48.05 53.43 52.32

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only 48.05 47.91 53.43 49.18 52.32
FRA:R9Z
6GF Score
ImmuneOnco Biopharmaceuticals (Shanghai) Inc FRA:R9Z
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmuneOnco Biopharmaceuticals (Shanghai) Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €52.32 Mil mean?
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a Common Stock of €52.32 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors.
Is ImmuneOnco Biopharmaceuticals (Shanghai)'s Common Stock too high?
ImmuneOnco Biopharmaceuticals (Shanghai)'s current Common Stock is €52.32 Mil. Overall, ImmuneOnco Biopharmaceuticals (Shanghai) has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does ImmuneOnco Biopharmaceuticals (Shanghai)'s Common Stock compare to VRTX and REGN?
ImmuneOnco Biopharmaceuticals (Shanghai)'s Common Stock of €52.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. ImmuneOnco Biopharmaceuticals (Shanghai)'s current Common Stock is €52.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuneOnco Biopharmaceuticals (Shanghai) stock overvalued right now?
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a current Common Stock of €52.32 Mil. The current Common Stock is €52.32 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z), the current Common Stock is €52.32 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Other Exchanges 01541:Hong Kong
Address 1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
6GF Score

Get the complete analysis for FRA:R9Z

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.37
Price